Your search returned over 250 studies. The top 250 studies are being displayed. Please use additional keywords or decrease the search distance. Get alerts for new studies
- Flavopiridol in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma
Conditions: Lymphoma - Multiple Myeloma and Plasma Cell Neoplasm
1 Location available
- Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia
Conditions: Leukemia
153 Locations available
- Bortezomib and Dexamethasone in Treating Patients With Multiple Myeloma That Has Relapsed or Has Not Responded to Treatment
Conditions: Multiple Myeloma and Plasma Cell Neoplasm
1 Location available
- Combination Chemotherapy in Treating Young Patients With Relapsed or Refractory Acute Leukemia
Conditions: Leukemia
1 Location available
- Safety, Efficacy, & Pharmacokinetic Study of Tamibarotene to Treat Patients With Relapsed or Refractory APL
Conditions: Acute Promyelocytic Leukemia
2 Locations available
- T-Lymphocytes in Treating Patients With Relapsed or Refractory Low-Grade B-Cell Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia
Conditions: Leukemia - Lymphoma
3 Locations available
- IDO Inhibitor Study for Relapsed or Refractory Solid Tumors
Conditions: Breast Cancer - Lung Cancer - Melanoma - Pancreatic Cancer - Solid Tumors
1 Location available
- Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors
Conditions: Adrenocortical Carcinoma - Kidney Cancer - Liver Cancer - Neuroblastoma - Retinoblastoma - Sarcoma
97 Locations available
- Idarubicin, Cytarabine, and Pravastatin in Treating Patients With Relapsed Acute Myeloid Leukemia
Conditions: Leukemia
82 Locations available
- Iodine I 131 Monoclonal Antibody BC8 Before Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-H
Conditions: Adult Nasal Type Extranodal NK/T-cell Lymphoma - Anaplastic Large Cell Lymphoma - Angioimmunoblastic T-cell Lymphoma - Cutaneous B-cell Non-Hodgkin Lymphoma - Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue - Hepatosplenic T-
1 Location available
- Study of Dasatinib and All-Trans Retinoic Acid for Relapsed/Refractory and/or Elderly Patients With Acute Myelogenous Leukemia (AML)
Conditions: Acute Myelogenous Leukemia
1 Location available
- Collecting and Storing Samples of Bone Marrow and Blood From Patients With Relapsed Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma
Conditions: Leukemia - Lymphoma
138 Locations available
- Epratuzumab, Cytarabine, and Clofarabine in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
Conditions: Leukemia
46 Locations available
- Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia
Conditions: Hairy Cell Leukemia
1 Location available
- Belinostat and Bortezomib in Treating Patients With Relapsed or Refractory Acute Leukemia or Myelodysplastic Syndrome
Conditions: Acute Lymphocytic Leukemia - Acute Myeloid Leukemia - Myelodysplastic Syndrome - Chronic Myelogenous Leukemia
1 Location available
- Patients With Relapsed or Refractory Diffuse Large B Cell Non Hodgkin Lymphomas
Conditions: Non-Hodgkin Lymphomas
2 Locations available
- Trial of PD 0332991 Plus Bortezomib in Patients With Relapsed Mantle Cell Lymphoma
Conditions: Mantle Cell Lymphoma
1 Location available
- Entinostat and Clofarabine in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Poor-Risk Acute Lymphoblastic Leukemia or Bilineage/Biph
Conditions: Leukemia
3 Locations available
- Pralatrexate and Bexarotene in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma
Conditions: Cutaneous T-cell Lymphoma - Mycosis Fungoides - Sezary Syndrome - Primary Cutaneous Anaplastic Large Cell Lymphoma
3 Locations available
- Phase II Study of VELCADE for Relapsed or Refractory T-cell Prolymphocytic Leukemia
Conditions: Leukemia - Leukemia Acute Lymphoid Leukemia (ALL)
1 Location available
- Panobinostat Plus Ifosfamide, Carboplatin, and Etoposide (ICE) Compared With ICE For Relapsed Hodgkin Lymphoma
Conditions: Hodgkin's Lymphoma
1 Location available
- Study of Vosaroxin or Placebo in Combination With Cytarabine in Patients With First Relapsed or Refractory Acute Myeloid Leukemia (AML)
Conditions: Leukemia - Acute Myeloid Leukemia - Acute Nonlymphocytic Leukemia
38 Locations available
- Nilotinib in Patients With Relapsed or Metastatic Pigmented Villonodular Synovitis/Tenosynovial Giant Cell Tumor/Diffuse-Type Giant Cell Tumor
Conditions: Pigmented Villonodular Synovitis - Diffuse-type Giant Cell Tumor - Tenosynovial Giant Cell Tumor
6 Locations available
- Study Examining the Combination of Lenalidomide and Azacitidine for Relapsed/Refractory CLL and SLL
Conditions: Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)
1 Location available
- Azacitidine in Combination With Mitoxantrone, Etoposide Phosphate, and Cytarabine in Treating Patients With Relapsed and Refractory Acute Myeloid Leuk
Conditions: Leukemia
1 Location available
- Single-Arm Open-Label Multicenter Study of VB-111 in Patients With Recurrent Glioblastoma Multiforme
Conditions: Relapsed Glioblastoma Multiforme
3 Locations available
- Panobinostat With Rituximab for Relapsed/Refractory Diffuse Large B Cell Lymphoma
Conditions: Diffuse Large B Cell Lymphoma
3 Locations available
- Panitumumab and Gemcitabine in Relapsed Ovarian Cancer
Conditions: Ovarian Cancer - Fallopian Tube Cancer - Primary Peritoneal Cancer
1 Location available
- Bortezomib and Bendamustine to Treat Relapsed/Refractory Myeloma
Conditions: Multiple Myeloma
1 Location available
- Cyclosporine, Pravastatin Sodium, Etoposide, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Conditions: Adult Acute Megakaryoblastic Leukemia (M7) - Adult Acute Minimally Differentiated Myeloid Leukemia (M0) - Adult Acute Monoblastic Leukemia (M5a) - Adult Acute Monocytic Leukemia (M5b) - Adult Acute Myeloblastic Leukemia With Maturation (M2) - Adult Acute
1 Location available
- Combination of BKM120 and Bevacizumab in Refractory Solid Tumors and Relapsed/Refractory Glioblastoma Multiforme
Conditions: Glioblastoma Multiforme
1 Location available
- Phase 2 Safety and Efficacy Study of CAL-101 (GS-1101) in Relapsed or Refractory Hodgkin Lymphoma
Conditions: Hodgkin Lymphoma
3 Locations available
- MLN8237 in Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Rituximab & Vincristine
Conditions: Diffuse Large B-Cell Lymphoma - Transformed Follicular Lymphoma - Mantle Cell Lymphoma - Burkitt's Lymphoma
1 Location available
- A Phase I Study of AC220 for Children With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia
Conditions: Lymphoblastic Leukemia, Acute, Childhood - Myelogenous Leukemia, Acute, Childhood
2 Locations available
- Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Pro
Conditions: Adult Nasal Type Extranodal NK/T-cell Lymphoma - Anaplastic Large Cell Lymphoma - Angioimmunoblastic T-cell Lymphoma - Cutaneous B-cell Non-Hodgkin Lymphoma - Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue - Hepatosplenic T-
1 Location available
- A Study to Evaluate the Use of Chloroquine in Combination With VELCADE and Cyclophosphamide in Patients With Relapsed and Refractory Multiple Myeloma
Conditions: Multiple Myeloma
1 Location available
- A Study of Oral LGH447 in Patients With Relapsed and/or Refractory Multiple Myeloma
Conditions: Multiple Myeloma
1 Location available
- A Phase II Trial of Panobinostat and Lenalidomide in Patients With Relapsed or Refractory Hodgkin's Lymphoma
Conditions: Adult Lymphocyte Depletion Hodgkin Lymphoma - Adult Lymphocyte Predominant Hodgkin Lymphoma - Adult Mixed Cellularity Hodgkin Lymphoma - Adult Nodular Lymphocyte Predominant Hodgkin Lymphoma - Adult Nodular Sclerosis Hodgkin Lymphoma - Recurrent Adult Hod
1 Location available
- Cyclophosphamide, Topotecan, and Bevacizumab (CTB) in Patients With Relapsed/Refractory Ewing's Sarcoma and Neuroblastoma
Conditions: Neuroblastoma - Sarcoma
1 Location available
- Study of the Combination of Panobinostat and Carfilzomib in Patients With Relapsed/Refractory Multiple Myeloma
Conditions: Multiple Myeloma
1 Location available
- Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer
Conditions: Head and Neck Cancer - Kidney Cancer - Liver Cancer - Sarcoma
48 Locations available
- Viral Therapy in Treating Patients With Relapsed or Refractory Multiple Myeloma
Conditions: Multiple Myeloma and Plasma Cell Neoplasm
1 Location available
- A Phase I Study of the Combination of Panobinostat and Carfilzomib in Patients With Relapsed and/or Refractory Multiple Myeloma
Conditions: Multiple Myeloma
1 Location available
- T-Lymphocytes in Treating Patients With Active or Relapsed Hodgkin Lymphoma or Non-Hodgkin Lymphoma
Conditions: Lymphoma - Precancerous Condition
3 Locations available
- Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral
Conditions: Leukemia - Lymphoma - Small Intestine Cancer
5 Locations available
- Cladribine, Cytarabine, and Imatinib Mesylate in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Blastic Phase Chronic Myeloge
Conditions: Leukemia
1 Location available
- Combination Chemotherapy and Alemtuzumab in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
Conditions: Leukemia
64 Locations available
- Hydroxychloroquine and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma
Conditions: Multiple Myeloma and Plasma Cell Neoplasm
1 Location available
- Combination Chemotherapy Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or High-Risk Primary Refractory Hodgkin Lymphoma
Conditions: Lymphoma
1 Location available
- Dose Escalation Trial of WT1-Sensitized T Cells for Residual or Relapsed Leukemia After Allogeneic Hematopoietic Progenitor Cell Transplantation
Conditions: Leukemia - Myelodysplastic Syndrome
1 Location available
- Sunitinib in Treating Patients With Relapsed or Refractory Esophageal or Gastroesophageal Junction Cancer
Conditions: Esophageal Cancer
1 Location available
- Bortezomib and Gemcitabine in Treating Patients With Relapsed B-Cell Non-Hodgkin Lymphoma
Conditions: Lymphoma
1 Location available
- Infusion of Genetically Modified T Cell for Post Transplant Patients With Relapsed Disease
Conditions: Leukemia - Lymphoma, Non-Hodgkin - Hodgkin Disease - Myelodysplastic Syndromes - Multiple Myeloma
1 Location available
- Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Children With Relapsed or Refractory High-Risk NBL.
Conditions: Neuroblastoma
4 Locations available
- Sorafenib in Combination With Cytarabine and Clofarabine in Patients With Refractory or Relapsed Hematologic Malignancies
Conditions: Acute Myeloid Leukemia - Infantile Leukemia (Both AML and ALL) - Myelodysplastic Syndrome - Myelodysplastic/Myeloproliferative Neoplasms - Biphenotypic Leukemia
1 Location available
- A Study to Evaluate the Safety and Efficacy of Dasatinib (Sprycel) in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Conditions: Diffuse Large B-cell Lymphoma
1 Location available
- Alvocidib and Oxaliplatin With or Without Fluorouracil and Leucovorin Calcium in Treating Patients With Relapsed or Refractory Germ Cell Tumors
Conditions: Extragonadal Germ Cell Tumor - Ovarian Cancer - Testicular Germ Cell Tumor
9 Locations available
- RAD001 Study in Treatment of Relapsed or Refractory Acute Lymphocytic Leukemia
Conditions: Leukemia - Acute Lymphocytic Leukemia
1 Location available
- Trial of Nelarabine, Etoposide and Cyclophosphamide in Relapsed T-cell ALL and T-cell LL
Conditions: Relapsed T-Cell Acute Lymphoblastic Leukemia - Relapsed T-Cell Lymphoblastic Lymphoma
20 Locations available
- A Phase I Trial Using Cyclophosphamide, Rituximab and Revlimid (CR2) for the Treatment of Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia (B-C
Conditions: Leukemia, Lymphocytic, Chronic, B-Cell - Chronic Lymphocytic Leukemia - Lymphoma, Small Lymphocytic
1 Location available
- Phase II Trial of Alemtuzumab (Campath) and Dose-Adjusted EPOCH-Rituximab (DA-EPOCH-R) in Relapsed or Refractory Diffuse Large B-Cell and Hodgkin Lymp
Conditions: Hodgkin Lymphoma - Diffuse Large B-Cell Lymphoma
1 Location available
- Study of Pazopanib and Doxil in Patients With Advanced Relapsed Platinum-Sensitive or Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal
Conditions: Ovarian Cancer - Fallopian Tube Cancer - Peritoneal Carcinoma
4 Locations available
- Ph2 PF-00299804 in Relapsed/Recurrent GBM
Conditions: Malignant Glioma
1 Location available
- Lenalidomide Plus Melphalan as a Preparative Regimen for Autologous Stem Cell Transplantation in Relapsed Multiple Myeloma: A Phase 1 / 2 Study
Conditions: Multiple Myeloma
1 Location available
- Bevacizumab, Irinotecan and Temozolomide for Relapsed or Refractory Neuroblastoma
Conditions: Neuroblastoma
1 Location available
- Low-Dose Azacitidine, Lenalidomide, and Low-Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma
Conditions: Refractory Multiple Myeloma
2 Locations available
- Entinostat and Sorafenib Tosylate in Treating Patients With Advanced or Metastatic Solid Tumors or Refractory or Relapsed Acute Myeloid Leukemia
Conditions: Leukemia - Unspecified Adult Solid Tumor, Protocol Specific
2 Locations available
- Rituximab for Patients With Relapsed Acute Lymphoblastic Leukemia
Conditions: Leukemia - Acute Lymphoblastic Leukemia - ALL
3 Locations available
- A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive
Conditions: Lymphoma, Non-Hodgkin - Lymphoma, B-cell - Lymphoma, B-cell, Diffuse
63 Locations available
- Carfilzomib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Relapsed or Refractory Multiple Myeloma
Conditions: Multiple Myeloma
1 Location available
- AKT Kinase Inhibitor MK-2206 With Relapsed Refractory Acute Myelogenous Leukemia
Conditions: Leukemia
1 Location available
- Sapacitabine, Cyclophosphamide, Rituximab for Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma (CLL/SLL) With Deletion (11q22-23)
Conditions: Leukemia
1 Location available
- Panobinostat in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
Conditions: Adult Nasal Type Extranodal NK/T-cell Lymphoma - Anaplastic Large Cell Lymphoma - Angioimmunoblastic T-cell Lymphoma - Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue - Hepatosplenic T-cell Lymphoma - Nodal Marginal Zone B-ce
2 Locations available
- Study of Velcade and Temsirolimus for Relapsed or Refractory Non-Hodgkin Lymphoma
Conditions: Non-Hodgkins Lymphoma
8 Locations available
- Ofatumumab and Bendamustine Followed by Maintenance Ofatumumab for Rituximab Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (B-NHL)
Conditions: Lymphoma, Non-Hodgkin
9 Locations available
- Biological Therapy, Sargramostim, and Isotretinoin in Treating Patients With Relapsed or Refractory Neuroblastoma
Conditions: Neuroblastoma
56 Locations available
- Proteasome Inhibitor MLN9708 in Treating Patients With Relapsed Multiple Myeloma That Is Not Refractory to Bortezomib
Conditions: Multiple Myeloma
3 Locations available
- HLA-Matched Allogeneic Cytotoxic T Lymphocytes (CTLs) for Treatment of Patients With Relapsed Epstein Barr Virus (EBV)-Associated Diseases
Conditions: Hodgkin Lymphoma - Non-Hodgkin Lymphoma - Lymphoproliferative Disorder - Nasopharyngeal Carcinoma - Leiomyosarcoma
2 Locations available
- Clinical Study With Blinatumomab in Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)
Conditions: Acute Lymphoblastic Leukemia
2 Locations available
- A Phase I Study of Ganetespib +/- Bortezomib in Patients With Relapsed and/or Refractory Multiple Myeloma
Conditions: Multiple Myeloma
1 Location available
- A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma
Conditions: Glioblastoma - Small Cell Glioblastoma - Giant Cell Glioblastoma - Gliosarcoma - Glioblastoma With Oligodendroglial Component - Recurrent Glioblastoma - Relapsed Glioblastoma
11 Locations available
- Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma
Conditions: Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue - Nodal Marginal Zone B-cell Lymphoma - Recurrent Adult Diffuse Large Cell Lymphoma - Recurrent Grade 1 Follicular Lymphoma - Recurrent Grade 2 Follicular Lymphoma - Recurrent G
1 Location available
- Ofatumumab and Dinaciclib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-Cell Prolymp
Conditions: Leukemia - Lymphoma
1 Location available
- Talactoferrin in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer or Squamous Cell Head and Neck Cancer
Conditions: Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma - Recurrent Metastatic Squamous Neck Cancer With Occult Primary - Recurrent Salivary Gland Cancer - Recurrent Squamous Cell Carcinoma of the Hypopharynx - Recurrent Squamous Cell
1 Location available
- Bortezomib, Rituximab, Cyclophosphamide, and Prednisone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma
Conditions: Leukemia - Lymphoma
4 Locations available
- Dose Escalation Study of Clofarabine in Patients With Relapsed or Refractory Low Grade or Intermediate-Grade B-Cell Lymphoma
Conditions: B-Cell Lymphoma
1 Location available
- Clofarabine and Cytarabine in Treating Young Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia
Conditions: Leukemia
70 Locations available
- A Phase II Study of Interaction of Lovastatin and Paclitaxel For Patients With Refractory or Relapsed Ovarian Cancer
Conditions: Ovarian Cancer
1 Location available
- Azacytidine and Bortezomib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes
Conditions: Leukemia - Myelodysplastic Syndromes - Myelodysplastic/Myeloproliferative Neoplasms
1 Location available
- Obatoclax and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma
Conditions: Multiple Myeloma and Plasma Cell Neoplasm
7 Locations available
- Evaluate Rituximab in Obtaining PCR Negative Leukapheresis Product in Patients With Relapsed Follicular Lymphoma
Conditions: Non-Hodgkins Lymphoma
2 Locations available
- JVRS-100 for the Treatment of Patients With Relapsed or Refractory Leukemia
Conditions: Leukemia
1 Location available
- A Pilot Study of the Safety and Activity of Escalating Doses of ON 01910.Na in Patients With Relapsed Mantle Cell Lymphoma, Multiple Myeloma, Chronic
Conditions: Lymphoma, Mantle-Cell - Leukemia, Lymphocytic, Chronic, B-Cell - Leukemia, Hairy Cell - Waldenstrom Macroglobulinemia - Multiple Myeloma
1 Location available
- Vorinostat, Gemtuzumab Ozogamicin, and Azacitidine in Treating Older Patients With Relapsed or Refractory Acute Myeloid Leukemia
Conditions: Leukemia
3 Locations available
- Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Treating Young Patients With Relapsed or Refracto
Conditions: Leukemia - Lymphoma - Unspecified Childhood Solid Tumor, Protocol Specific
18 Locations available
- Study Evaluating the Safety and Tolerability of Weekly Dosing of Oral MLN9708 in Adult Patients With Relapsed and Refractory Multiple Myeloma
Conditions: Relapsed and Refractory Multiple Myeloma
6 Locations available
- A Clinical Study Using MEDI-551 in Adult Subjects With Relapsed or Refractory Advanced B-Cell Malignancies
Conditions: B-cell Malignancies
6 Locations available
- Peripheral Blood Stem Cell (PBSC) Mobilization in Patients With Relapsed Lymphoma Treated With Bendamustine
Conditions: Lymphoma
1 Location available
- Safety Study: Combination of Decitabine and Midostaurin in Patients Older Than 60 With Newly Diagnosed or Relapsed Refractory Acute Myeloid Leukemia
Conditions: Acute Myeloid Leukemia
1 Location available
- Cladribine Based Induction Therapy With All-Trans Retinoic Acid and Midostaurin in Relapsed/Refractory AML
Conditions: Leukemia, Myeloid, Acute
1 Location available
- Multi-center Trial of Revlimid® and Rituximab for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
Conditions: Chronic Lymphocytic Leukemia - CLL
1 Location available
- Study of CX-4945 in Patients With Relapsed or Refractory Multiple Myeloma
Conditions: Multiple Myeloma
6 Locations available
- Study of IMMU-130 in Patients With Relapsed/Refractory Colorectal Cancer
Conditions: Metastatic Colorectal Cancer
1 Location available
- Continuous Versus Intermittent Dosing Regimens for Pomalidomide in Relapsed/Refractory Multiple Myeloma
Conditions: Multiple Myeloma
1 Location available
- Infusional Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma
Conditions: Multiple Myeloma
1 Location available
- A Phase II Study Of Imtox-25 In Adults With Refractory/Relapsed Cd25 Positive Adult T Cell Leukemia/Lymphoma
Conditions: Adult T Cell Leukemia - Adult T Cell Lymphoma
12 Locations available
- Ofatumumab and Bortezomib in Subjects With Relapsed CD20+ NHL
Conditions: Recurrent Adult Diffuse Large Cell Lymphoma - Recurrent Grade 1 Follicular Lymphoma - Recurrent Grade 2 Follicular Lymphoma - Recurrent Grade 3 Follicular Lymphoma - Recurrent Mantle Cell Lymphoma
1 Location available
- Phase 1 Study of Combotox With Cytarabine in Relapsed/Refractory B-lineage Acute Lymphoblastic Leukemia (ALL)
Conditions: B-cell Adult Acute Lymphoblastic Leukemia - Acute Lymphoblastic Leukemia
1 Location available
- Trial of pasireotideLAR and Topotecan in Relapsed or Refractory Small Cell Lung Cancer
Conditions: Small Cell Lung Cancer
1 Location available
- A Study of DFRF4539A in Patients With Relapsed or Refractory Multiple Myeloma
Conditions: Multiple Myeloma
3 Locations available
- Study of Donor Derived, Multi-virus-specific, Cytotoxic T-Lymphocytes for Relapsed/Refractory Neuroblastoma
Conditions: Neuroblastoma
1 Location available
- Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma
Conditions: Multiple Myeloma
16 Locations available
- Phase II Ofatumumab/Methylprednisolone Followed by Ofatumumab/Lenalidomide for Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic L
Conditions: Chronic Lymphocytic Leukemia (CLL) - Small Lymphocytic Lymphoma (SLL)
1 Location available
- Phase II Trial of Mitogen Activated Protein (MAP) Kinase Inhibition With AZD6244 and MK-2206 (Akt Inhibitor) in Patients With Relapsed (BRAF) V600E Mu
Conditions: Melanoma
1 Location available
- Ofatumumab Plus Bendamustine in Frontline and Relapsed Chronic Lymphocytic Leukaemia (CLL)
Conditions: Leukaemia, Lymphocytic, Chronic
3 Locations available
- Randomized Phase II Study of Single Agent OSI-906 Versus Topotecan for Relapsed Small Cell Lung Cancer (SCLC)
Conditions: Lung Cancer
1 Location available
- ACE-011 With Lenalidomide+Dexamethasone for Relapsed/Refractory Multiple Myeloma
Conditions: Multiple Myeloma
1 Location available
- LMP-specific T-cells for Patients With Relapsed EBV-positive Lymphoma
Conditions: Hodgkin Disease - Non Hodgkin Lymphoma
3 Locations available
- Phase I/II Trial of VELCADE Plus Zevalin in Patients With Relapsed or Refractory Follicular Lymphoma
Conditions: Lymphoma
4 Locations available
- Iodine I 131 Monoclonal Antibody 3F8 and Bevacizumab in Treating Patients With Relapsed or Refractory Neuroblastoma
Conditions: Neuroblastoma
1 Location available
- Phase 1 Clinical Trial of NPI-0052 in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma
Conditions: Multiple Myeloma
5 Locations available
- Sorafenib and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma
Conditions: Lymphoma - Multiple Myeloma and Plasma Cell Neoplasm
2 Locations available
- Vaccination for the Treatment of Previously Untreated or Relapsed Follicular Lymphoma
Conditions: Follicular Lymphoma
1 Location available
- Intensity-Modulated Radiation Therapy, Etoposide, and Cyclophosphamide Followed By Donor Stem Cell Transplant in Treating Patients With Relapsed or Re
Conditions: Leukemia
1 Location available
- Study of Nifurtimox to Treat Refractory or Relapsed Neuroblastoma or Medulloblastoma
Conditions: Neuroblastoma - Medulloblastoma
7 Locations available
- Oral Clofarabine for Relapsed/Refractory Indolent B-cell NHL and Mantle Cell Lymphoma
Conditions: Follicular Lymphoma - Marginal Zone Lymphoma - Mantle Cell Lymphoma - Small Lymphocytic Lymphoma - Lymphoplasmacytic Lymphoma - Low Grade B-cell Lymphoma, Not Otherwise Specified
2 Locations available
- Pentostatin, Alemtuzumab, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Conditions: Leukemia - Lymphoma
3 Locations available
- Autologous and Allogeneic Transplant for Relapsed Lymphoma
Conditions: Non-Hodgkin's Lymphoma - Hodgkins Disease
1 Location available
- Clofarabine and Cytarabine in Treating Older Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes That Have Relapsed or Not Res
Conditions: Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities - Adult Acute Myeloid Leukemia With Del(5q) - Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) - Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) - Adult Acute Myeloid Leukemia With t(8;21)(
1 Location available
- Lenalidomide and Rituximab in Treating Patients With Follicular or Small Lymphocytic Non-Hodgkin Lymphoma That Has Relapsed or Not Responded to Treatm
Conditions: Lymphoma
1 Location available
- Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
Conditions: Leukemia - Lymphoma
97 Locations available
- Effectiveness of a Blood Stem Cell Transplant That Uses Low Dose Chemotherapy in People With Relapsed Follicular Non-Hodgkin's Lymphoma (BMT CTN #0701
Conditions: Lymphoma, Non-Hodgkin
34 Locations available
- Open-label Study to Evaluate the Safety, PK, and PD of MEK Inhibitor GSK1120212 in Subjects With Relapsed or Refractory Leukemias
Conditions: Leukemia-relapsed or Refractory - Cancer
13 Locations available
- Host Dendritic Cells in Allograft Patients
Conditions: Relapsed Non-Hodgkin's Lymphoma - Hodgkin's Disease - Multiple Myeloma - Chronic Lymphocytic Lymphoma
1 Location available
- Bendamustine as Second-Line Therapy in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer
Conditions: Lung Cancer
2 Locations available
- Bendamustine Hydrochloride, Lenalidomide, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma
Conditions: Refractory Multiple Myeloma
5 Locations available
- A Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple Myeloma
Conditions: Multiple Myeloma
9 Locations available
- Lenalidomide and Temsirolimus in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma
Conditions: Lymphoma
11 Locations available
- Azacitidine in Treating Patients With Relapsed Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Who Have Undergone
Conditions: Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities - Adult Acute Myeloid Leukemia With Del(5q) - Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) - Adult Acute Myeloid Leukemia With t(15;17)(q22;q12) - Adult Acute Myeloid Leukemia With t(16;16)
1 Location available
- Dinaciclib in Treating Patients With Relapsed or Refractory Multiple Myeloma
Conditions: Multiple Myeloma and Plasma Cell Neoplasm
9 Locations available
- Study of Hsp90 Inhibitor, STA-9090 for Relapsed or Refractory Small Cell Lung Cancer
Conditions: Small Cell Lung Cancer
3 Locations available
- A Phase 1/2 Study of PF-02341066, An Oral Small Molecule Inhibitor of Anaplastic Lymphoma Kinase (ALK) and C-Met, in Children With Relapsed/Refractory
Conditions: Wilms Tumor - Sarcoma - Neuroblastoma - Osteosarcoma - Lymphoma, Large Cell, Anaplastic
2 Locations available
- Effect of AT7519M Alone and AT7519M Plus Bortezomib in Patients With Previously Treated Multiple Myeloma
Conditions: Multiple Myeloma - Relapsed Multiple Myeloma - Refractory Multiple Myeloma
5 Locations available
- Pomalidomide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
Conditions: Refractory Multiple Myeloma
1 Location available
- Study of MK-2206 in Patients With Relapsed Lymphoma
Conditions: Lymphoma
1 Location available
- Trial Of Repeated Super-selective Intraarterial Cerebral Infusion Of Bevacizumab (Bevacizumab) For Treatment Of Relapsed/Refractory Glioblastoma Multi
Conditions: Glioblastoma Multiforme - Anaplastic Astrocytoma
1 Location available
- A Study of Escalating Doses of DCDS4501A in Patients With Relapsed or Refractory B-Cell Non Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia
Conditions: Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia
5 Locations available
- Clinical Study of Vorinostat in Combination With Etoposide in Pediatric Patients < 21 Years at Diagnosis With Refractory Solid Tumors
Conditions: Solid Tumors - Relapsed/Refractory Sarcomas
2 Locations available
- A Study of Carfilzomib, Lenalidomide, Vorinostat, and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
Conditions: Multiple Myeloma
1 Location available
- Study of MLN2480 in Patients With Relapsed or Refractory Solid Tumors Followed by a Dose Expansion in Patients With Metastatic Melanoma
Conditions: Melanoma - Metastatic Melanoma - Solid Tumor
2 Locations available
- A Phase 2, Multicenter, Randomized, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Conditions: Diffuse Large B-Cell Lymphoma (DLBCL)
5 Locations available
- IIT CTI Bendamustine, Rituximab, Pixantrone in Relapsed/Refractory B Cell Non-Hodgkin's Lymphoma
Conditions: Non-Hodgkin's Lymphoma
1 Location available
- Study of Brentuximab Vedotin (SGN-35) in Pediatric Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma or Hodgkin Lymphoma
Conditions: Hodgkin Lymphoma - Anaplastic Large-cell Lymphoma
3 Locations available
- Auto Transplant for High Risk or Relapsed Solid Tumor
Conditions: Hematopoietic Stem Cell Transplantation - Solid Tumor - Transplantation, Autologous
1 Location available
- Linsitinib or Topotecan Hydrochloride in Treating Patients With Relapsed Small Cell Lung Cancer
Conditions: Lung Cancer
9 Locations available
- Gemcitabine and Bendamustine in Patients With Relapsed or Refractory Hodgkin's Lymphoma
Conditions: Adult Lymphocyte Depletion Hodgkin Lymphoma - Adult Lymphocyte Predominant Hodgkin Lymphoma - Adult Mixed Cellularity Hodgkin Lymphoma - Adult Nodular Lymphocyte Predominant Hodgkin Lymphoma - Adult Nodular Sclerosis Hodgkin Lymphoma - Recurrent Adult Hod
1 Location available
- Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia
Conditions: Leukemia - Unspecified Childhood Solid Tumor, Protocol Specific
21 Locations available
- GM-CSF and Rituximab After Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Follicular Non-Hodgkin Lymphoma
Conditions: Lymphoma
1 Location available
- Dasatinib in Relapsed or Refractory Non-Hodgkin's Lymphoma
Conditions: Non-Hodgkin's Lymphoma
1 Location available
- Donor Stem Cell Transplant in Treating Young Patients With Acute Myeloid Leukemia With Monosomy 7, -5/5q-, High FLT3-ITD AR, or Refractory or Relapsed
Conditions: Leukemia
48 Locations available
- Bortezomib and Lenalidomide in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma
Conditions: Lymphoma
41 Locations available
- Bortezomib, Ifosfamide, Carboplatin, and Etoposide, With or Without Rituximab, in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgk
Conditions: Lymphoma
12 Locations available
- Total Marrow Irradiation Added to an Alkylator-Intense Conditioning Regimen for Patients With High Risk or Relapsed Solid Tumors
Conditions: Brain and Central Nervous System Tumors - Kidney Cancer - Liver Cancer - Retinoblastoma - Sarcoma
1 Location available
- Busulfan, Melphalan, Topotecan Hydrochloride, and a Stem Cell Transplant in Treating Patients With Newly Diagnosed or Relapsed Solid Tumor
Conditions: Solid Tumor - Adult Central Nervous System Germ Cell Tumor - Adult Rhabdomyosarcoma - Childhood Central Nervous System Germ Cell Tumor - Childhood Soft Tissue Sarcoma - Ewing Sarcoma - Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor -
1 Location available
- Everolimus and Bortezomib in Treating Patients With Relapsed or Refractory Lymphoma
Conditions: 714leukemia - Lymphoma
1 Location available
- Gleevec in Relapsed/Refractory T Cell Non-Hodgkin's Lymphoma
Conditions: T Cell Non-Hodgkin Lymphoma
1 Location available
- A Phase 1 Safety Study of LY2127399 in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma
Conditions: Relapsed or Refractory Multiple Myeloma
6 Locations available
- Rituximab, Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Low-Grade Follicular Lymphoma, Waldenstrom
Conditions: Lymphoma
2 Locations available
- Sorafenib in Treating Non-Smokers or Former Light Smokers With Relapsed or Refractory Stage IIIB or Stage IV Non-Small Cell Lung Cancer
Conditions: Lung Cancer
1 Location available
- Vorinostat, Cladribine, and Rituximab in Treating Patients With Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia, or Relapsed B-Cell Non-Hodgkin Lym
Conditions: Leukemia - Lymphoma
1 Location available
- Study of Irinotecan and Bevacizumab With Temozolomide in Refractory/Relapsed Central Nervous System (CNS) Tumors
Conditions: Central Nervous System Tumors
1 Location available
- Study of Bendamustine/Rituxan Induction Chemotherapy With Revlimid Maintenance for Relapsed/Refractory CLL and SLL
Conditions: Chronic Lymphocytic Leukemia - Small Lymphocytic Lymphoma
10 Locations available
- Safety and Dose Determining Multi-dose Study of BT062 in Patients With Relapsed or Refractory Multiple Myeloma
Conditions: Multiple Myeloma
5 Locations available
- Bortezomib in Treating Patients With Relapsed or Refractory AIDS-Related Kaposi Sarcoma
Conditions: Sarcoma
7 Locations available
- Aurora A Kinase Inhibitor MLN8237 and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma
Conditions: Refractory Multiple Myeloma
6 Locations available
- Study to Investigate CAL-101 in Combination With Chemotherapeutic Agents and CD20 mAb in Patients With Relapsed or Refractory Indolent B-cell Non-Hodg
Conditions: Indolent Non-Hodgkin's Lymphoma - Chronic Lymphocytic Leukemia - Mantle Cell Lymphoma
11 Locations available
- Study of Veltuzumab and 90Y-Epratuzumab in Relapsed/Refractory, Aggressive NHL
Conditions: Non Hodgkin's Lymphoma - NHL - Aggressive NHL
3 Locations available
- CMC-544 in Relapsed Refractory Acute Lymphoblastic Leukemia (ALL)
Conditions: Acute Lymphoblastic Leukemia
1 Location available
- Temsirolimus, Irinotecan Hydrochloride, and Temozolomide in Treating Young Patients With Relapsed or Refractory Solid Tumors
Conditions: Unspecified Childhood Solid Tumor, Protocol Specific
21 Locations available
- Study of Decadron, Biaxin, and Pomalidomide in Relapsed/Refractory Myeloma
Conditions: Multiple Myeloma
1 Location available
- Bendamustine Hydrochloride, Rituximab, Etoposide, and Carboplatin in Treating Patients With Relapsed or Refractory Lymphoid Malignancies and Select Un
Conditions: Adult Grade III Lymphomatoid Granulomatosis - Adult Nasal Type Extranodal NK/T-cell Lymphoma - Anaplastic Large Cell Lymphoma - Angioimmunoblastic T-cell Lymphoma - Chronic Lymphocytic Leukemia - Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma - Con
1 Location available
- Safety and Efficacy Study of TRU-016 Plus Bendamustine vs. Bendamustine in Relapsed Chronic Lymphocytic Leukemia
Conditions: Chronic Lymphocytic Leukemia (CLL)
7 Locations available
- A Study of the Safety and Pharmacokinetics of Escalating Doses of DCDT2980S in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma and
Conditions: Chronic Lymphocytic Leukemia - Non-Hodgkin's Lymphoma
6 Locations available
- Lenalidomide and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Conditions: Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities - Recurrent Adult Acute Myeloid Leukemia
1 Location available
- A Study of ARRY-520 and Bortezomib Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma
Conditions: Multiple Myeloma, Plasma Cell Leukemia
3 Locations available
- Bortezomib, Vorinostat and Dexamethasone for Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL)
Conditions: Acute Lymphoblastic Leukemia
1 Location available
- Phase II Study of Simvastatin for Relapsed/Refractory Myeloma
Conditions: Myeloma
1 Location available
- Phase I/II Amrubicin in Combo With Lenalidomide + Weekly Dexamethasone in Relapsed/Refractory Multiple Myeloma
Conditions: Multiple Myeloma
1 Location available
- A Phase II Study of Amrubicin in Relapsed or Refractory Thymic Malignancies
Conditions: Thymoma - Thymus Cancer - Thymic Carcinoma
1 Location available
- Study of Carfilzomib for Multiple Myeloma Patients Who Are Relapsed/Refractory to Bortezomib-containing Treatments
Conditions: Multiple Myeloma
8 Locations available
- Single Agent Lenalidomide in Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia
Conditions: Leukemia - Adult Acute Lymphocytic Leukemia
1 Location available
- Decitabine and Vaccine Therapy for Patients With Relapsed AML Following Allogeneic Stem Cell Transplantation
Conditions: Acute Myelogenous Leukemia
1 Location available
- A Pilot Study of Decitabine and Vorinostat With Chemotherapy for Relapsed ALL
Conditions: Acute Lymphoblastic Leukemia - Precursor B-Cell Lymphoblastic Leukemia - Precursor T-Cell Lymphoblastic Leukemia
2 Locations available
- Alisertib in Treating Patients With Relapsed or Refractory Peripheral T-Cell Non-Hodgkin Lymphoma
Conditions: Lymphoma
126 Locations available
- Phase I Study of Panobinostat + Bortezomib for Relapsed and/or Refractory Mantle Cell Lymphoma (MCL)
Conditions: Mantle Cell Lymphoma
1 Location available
- Open-label Study of TH-302 as Monotherapy and in Combination With Bortezomib in Subjects With Relapsed/Refractory Multiple Myeloma
Conditions: Multiple Myeloma
2 Locations available
- IMGN529 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Conditions: Lymphoma, Non-Hodgkin
2 Locations available
- Autologous Stem Cell Transplant Followed By Donor Stem Cell Transplant In Treating Patients With Relapsed or Refractory Lymphoma
Conditions: Adult Nasal Type Extranodal NK/T-cell Lymphoma - Anaplastic Large Cell Lymphoma - Angioimmunoblastic T-cell Lymphoma - Burkitt Lymphoma - Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue - Nodal Marginal Zone B-cell Lymphoma -
2 Locations available
- Donor Lymphocyte Infusion in Treating Patients With Persistent, Relapsed, or Progressing Cancer After Donor Hematopoietic Cell Transplant
Conditions: Accelerated Phase Chronic Myelogenous Leukemia - Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities - Adult Acute Myeloid Leukemia With Del(5q) - Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) - Adult Acute Myeloid Leukemia With t(15;17)(q22;
2 Locations available
- Vorinostat, Cytarabine, and Etoposide in Treating Patients With Relapsed and/or Refractory Acute Leukemia or Myelodysplastic Syndromes or Myeloprolife
Conditions: Chronic Myeloproliferative Disorders - Leukemia - Myelodysplastic Syndromes - Myelodysplastic/Myeloproliferative Neoplasms
2 Locations available
- Study of VELCADE® With Mitoxantrone and Etoposide for Leukemias
Conditions: Relapsed Acute Leukemia - Refractory Acute Leukemia
1 Location available
- VEGF Trap in Treating Patients With Stage II or Stage III Multiple Myeloma That Has Relapsed or Not Responded to Previous Treatment
Conditions: Multiple Myeloma and Plasma Cell Neoplasm
5 Locations available
- Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors and Multiple Myeloma
Conditions: Ovarian Cancer - Renal Cancer - Non-small Cell Lung Cancer - Small Cell Lung Cancer - Solid Tumors - Multiple Myeloma
7 Locations available
- Dose Escalation Phase I/II Study of Lovastatin With High-Dose Cytarabine for Refractory or Relapsed AML
Conditions: Acute Myeloid Leukemia
1 Location available
- Reduced Intensity Conditioning With Clofarabine, Antithymocyte Globulin (ATG), Total Lymphoid Irradiation (TLI) Followed by Allogeneic Stem Cell Trans
Conditions: Acute Myeloid Leukemia - Myelodysplastic Syndrome - Acute Lymphocytic Leukemia - Relapsed/Refractory Chronic Lymphocytic Leukemia - Relapsed/Refractory Non Hodgkin's Lymphoma - Hodgkins Disease - Relapsed Refractory Multiple Myeloma
2 Locations available
- A Trial of the Combination 5-azacitidine and Gemtuzumab Ozogamicin Therapy for Treatment of Relapsed Acute Myeloid Leukemia (AML)
Conditions: Acute Myeloid Leukemia
2 Locations available
- Phase 1 Study of Radiosensitization Using Bortezomib in Relapsed Non-Hodgkin's Lymphoma Patients Receiving Radioimmunotherapy
Conditions: Non-Hodgkin's Lymphoma
2 Locations available
- A Pilot Study of the Addition of Bevacizumab to VOIT Regimen for Relapsed/Refractory Pediatric Solid Tumors
Conditions: Solid Tumor
1 Location available
- Topotecan and Doxorubicin in Treating Patients With Small Cell Lung Cancer That Has Relapsed or Not Responded to Treatment
Conditions: Recurrent Small Cell Lung Cancer
1 Location available
- A Study of Decitabine in Combination With Escalating Doses of Rapamycin in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Conditions: Acute Myeloid Leukemia
1 Location available
- A Study of the Safety and Preliminary Efficacy of Oral Midostaurin (PKC412) in Relapsed or Refractory Pediatric Leukemia
Conditions: Acute Myeloid Leukemia - Acute Lymphoblastic Leukemia
4 Locations available
- DT2219ARL Immunotoxin in Treating Patients With B-Cell Leukemia or Lymphoma That Has Relapsed or Not Responded to Treatment
Conditions: Leukemia - Lymphoma
3 Locations available
- Crizotinib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma
Conditions: Brain and Central Nervous System Tumors - Lymphoma - Neuroblastoma - Unspecified Childhood Solid Tumor, Protocol Specific
25 Locations available
- Phase 3 Study of Tavocept Versus Placebo in Patients With Newly Diagnosed or Relapsed Advanced Primary Adenocarcinoma of the Lung Treated With Docetax
Conditions: Non-small Cell Lung Cancer
4 Locations available
- Epigenetic Modulation in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Conditions: Diffuse Large B-cell Lymphoma
1 Location available
- Study of Pralatrexate to Treat Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
Conditions: Lymphoma, B-Cell
10 Locations available
- A Phase I Study of Indenoisoquinolines LMP400 and LMP776 in Adults With Relapsed Solid Tumors and Lymphomas
Conditions: Neoplasms - Lymphoma
1 Location available
- Safety Study for Refractory or Relapsed Neuroblastoma With DFMO Alone and in Combination With Etoposide
Conditions: Neuroblastoma
5 Locations available
- A Phase I Clinical Trial of OXi4503 for Relapsed and Refractory AML and MDS
Conditions: Leukemia, Myelogenous, Acute - Myelodysplastic Syndromes
1 Location available
- Phase I Bortezomib (VELCADE) in Combo With Pralatrexate in Relapsed/Refractory MM
Conditions: Multiple Myeloma
1 Location available
- Alvespimycin Hydrochloride in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-Cell Prolymphocytic Leuke
Conditions: Leukemia - Lymphoma
1 Location available
- Bortezomib, Mitoxantrone, Etoposide, and Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia
Conditions: Adult Acute Megakaryoblastic Leukemia (M7) - Adult Acute Minimally Differentiated Myeloid Leukemia (M0) - Adult Acute Monoblastic Leukemia (M5a) - Adult Acute Monocytic Leukemia (M5b) - Adult Acute Myeloblastic Leukemia With Maturation (M2) - Adult Acute
1 Location available
- INCB18424 in Treating Young Patients With Relapsed or Refractory Solid Tumor, Leukemia, or Myeloproliferative Disease
Conditions: Chronic Myeloproliferative Disorders - Leukemia - Myelodysplastic Syndromes - Myelodysplastic/Myeloproliferative Neoplasms - Unspecified Childhood Solid Tumor, Protocol Specific
24 Locations available
- Dasatinib With Fludarabine and Rituximab in Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Conditions: Chronic Lymphocytic Leukemia - Small Lymphocytic Lymphoma
2 Locations available
- Bortezomib and Midostaurin With or Without Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Conditions: Acute Myeloid Leukemia - Acute Myeloid Leukemia With Multilineage Dysplasia Following - Myelodysplastic Syndrome - Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities - Adult Acute Myeloid Leukemia With Del(5q) - Adult Acute Myeloid Leukemia With
1 Location available
- Single Agent Ofatumumab Vs. Single Agent Rituximab in Follicular Lymphoma Relapsed After Rituximab-Containing Therapy
Conditions: Lymphoma, Follicular
14 Locations available
- Vaccine Therapy With or Without Cryosurgery in Treating Patients With Residual, Relapsed, or Refractory B-Cell Non-Hodgkin Lymphoma
Conditions: Cutaneous B-cell Non-Hodgkin Lymphoma - Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue - Intraocular Lymphoma - Nodal Marginal Zone B-cell Lymphoma - Recurrent Adult Diffuse Large Cell Lymphoma - Recurrent Adult Diffuse Mixe
1 Location available
- Study of ADI-PEG 20 in Patients With Relapsed Sensitive or Refractory Small Cell Lung Cancer
Conditions: Small Cell Lung Cancer
1 Location available
- Study of HCD122 (Lucatumumab) and Bendamustine Combination Therapy in CD40+ Relapsed Follicular Lymphoma
Conditions: Follicular Lymphoma
3 Locations available
- High-Dose 131I-MIBG Therapy Combined With Vincristine and Five Days of Irinotecan for Resistant/Relapsed Neuroblastoma
Conditions: Neuroblastoma
1 Location available
- Study of Oral MLN9708 in Adult Patients With Relapsed or Refractory Light Chain Amyloidosis
Conditions: Light-Chain Amyloidosis
6 Locations available
- Study to Evaluate Two Lenalidomide Dose Regimens With Low Dose Dexamethasone for the Treatment Relapsed Multiple Myeloma
Conditions: Relapsed Multiple Myeloma
6 Locations available
- Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or
Conditions: Cognitive/Functional Effects - Fatigue - Lymphoma - Neurotoxicity - Therapy-related Toxicity
6 Locations available
- Ruxolitinib Phosphate (Oral JAK Inhibitor INCB18424) in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell or Peripheral T-Cell Non-Ho
Conditions: Peripheral T-cell Lymphoma - Recurrent Adult Diffuse Large Cell Lymphoma - Recurrent Adult T-cell Leukemia/Lymphoma
1 Location available
- Entinostat and Lapatinib Ditosylate in Patients With Locally Recurrent or Distant Relapsed Metastatic Breast Cancer Previously Treated With Trastuzuma
Conditions: Breast Cancer
1 Location available
- Oral Azacitidine as a Single Agent and in Combination With Carboplatin or Abraxane® in Subjects With Relapsed or Refractory Solid Tumors
Conditions: Relapsed or Refractory Solid Tumors
4 Locations available
- Zevalin and Velcade in Relapsed/Refractory Mantle Cell Lymphoma
Conditions: Mantle-Cell Lymphoma
1 Location available
- A Pilot Study of Sorafenib Examining Biomarkers in Refractory or Relapsed T-Cell Lymphoma Patients
Conditions: T Cell Lymphoma
1 Location available
- Pentostatin, Cyclophosphamide, and Rituximab Followed By Alemtuzumab in Treating Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leuke
Conditions: Leukemia
140 Locations available
- Fenretinide in Treating Patients With Refractory or Relapsed Hematologic Cancer
Conditions: Chronic Myeloproliferative Disorders - Leukemia - Lymphoma - Multiple Myeloma and Plasma Cell Neoplasm
4 Locations available
- Therapy for Pediatric Relapsed or Refractory Acute Lymphoblastic Leukemia
Conditions: Acute Lymphoblastic Leukemia - Lymphoma, Lymphoblastic
2 Locations available
- ABT-888 and Topotecan With or Without Carboplatin in Treating Patients With Relapsed or Refractory Acute Leukemia, High-Risk Myelodysplasia, or Aggres
Conditions: Chronic Myeloproliferative Disorders - Leukemia - Myelodysplastic Syndromes
1 Location available
- A Study to Determine the Efficacy and Safety of Lenalidomide in Patients With Mantle Cell NHL Who Have Relapsed or Progressed After Treatment With Bor
Conditions: Mantle Cell Lymphoma
26 Locations available
- A Study of ARRY-520 in Patients With Relapsed or Refractory Multiple Myeloma
Conditions: Multiple Myeloma - Plasma Cell Leukemia
5 Locations available
- Study of Fluphenazine in Relapsed or Relapsed-and-Refractory Multiple Myeloma
Conditions: Multiple Myeloma
2 Locations available
- Temsirolimus for Relapsed/Refractory Hodgkin's Lymphoma
Conditions: Hodgkin's Lymphoma
1 Location available
- Mismatched Donor Lymphocyte Infusions for Relapsed Disease Following Allogeneic Stem Cell Transplantation
Conditions: Leukemia, Myeloid, Acute - Leukemia, Lymphoblastic, Acute - Leukemia, Myelocytic, Chronic
1 Location available
- Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-Cell Lymphoma
Conditions: Childhood Diffuse Large Cell Lymphoma - Childhood Immunoblastic Large Cell Lymphoma - Cutaneous B-cell Non-Hodgkin Lymphoma - Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue - Intraocular Lymphoma - Nodal Marginal Zone B-cell
1 Location available
- Combination Plerixafor (AMD3100)and Bortezomib in Relapsed or Relapsed/Refractory Multiple Myeloma
Conditions: Multiple Myeloma
1 Location available
- A Phase I Study of GNKG186 in Patient With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL)
Conditions: Leukemia
4 Locations available
|